论文部分内容阅读
目的观察含力克肺疾方案治疗合并乙肝病毒感染的肺结核患者抗结核疗效及其安全性。方法78例合并乙肝病毒感染的肺结核患者应用含力克肺疾方案抗结核治疗,疗程7~9个月,观察疗效及肝功能情况。结果78例病人均完成疗程,总有效率97.4%,肝脏受损率11.5%,均为轻度。结论含力克肺疾方案3DEZV/4-6DE治疗合并乙肝病毒感染的肺结核疗效肯定,耐受性强,不良反应少,使用安全,值得推广。
Objective To observe the curative effect and safety of anti-tuberculosis therapy in patients with pulmonary tuberculosis complicated with hepatitis B virus infection. Methods Totally 78 tuberculosis patients with hepatitis B virus infection were treated with anti-tuberculosis therapy including Lectra Pulmonary Disease. The course of treatment was 7 to 9 months. The curative effect and liver function were observed. Results 78 patients completed the course of treatment, the total effective rate was 97.4%, liver damage rate was 11.5%, were mild. Conclusions The 3DEZV / 4-6DE containing Lectra pulmonary disease regimen is effective in treating pulmonary tuberculosis complicated with hepatitis B virus infection, with strong tolerance, few adverse reactions, safe use and worthy of promotion.